Labcorp Holdings Inc. and Illumina Inc. announced an expansion of their precision‑oncology partnership that will extend access to advanced biomarker testing across hospitals and community health systems.
The expanded collaboration introduces distributed biomarker testing, co‑commercializing Labcorp’s FDA‑authorized liquid‑biopsy assay PGDx elio® plasma focus™ Dx, which received De Novo marketing authorization from the FDA on August 2, 2024, and Illumina’s FDA‑approved TruSight™ Oncology Comprehensive for solid‑tumor profiling, approved on August 27, 2024. The joint effort will also bring whole‑genome sequencing to a broader range of clinical settings.
Labcorp says the expansion will accelerate evidence generation for payer coverage and support the development of new tests that address unmet needs in oncology. By broadening testing access, the partnership aims to increase the adoption of next‑generation sequencing (NGS) and provide clinicians with a more comprehensive genomic profile for patients, a strategy that aligns with the projected growth of the precision‑oncology market to over $200 billion by 2030.
Traci Pawlowski, VP of Clinical Product Development at Illumina, said, 'By deepening our collaboration, we'll continue to leverage the strengths of our respective teams to innovate and improve access to critical biomarker testing for patients with cancer.' Shakti Ramkissoon, MD, PhD, MBA, VP and Medical Lead for Oncology at Labcorp, added, 'This collaboration reflects Labcorp and Illumina's shared commitment to improving cancer care through innovation and access. Building on our longstanding medical and scientific collaborations and our ongoing efforts to generate clinical evidence and expand access to advanced genomics, we are combining our expertise to deliver transformative testing solutions that support more timely, equitable cancer care.'
The announcement prompted a positive market reaction, with Illumina’s shares rising 1.8% after the news. Analysts highlighted that the expansion is expected to boost NGS oncology adoption, broaden testing access, and drive growth in precision cancer care.
The partnership positions both companies to capture a larger share of the rapidly expanding precision‑oncology market, strengthens Labcorp’s specialty testing mix, and enhances Illumina’s commercial footprint in clinical diagnostics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.